iCAD (NASDAQ:ICAD) Trading Up 9.7%
iCAD Inc (NASDAQ:ICAD) shot up 9.7% during trading on Friday . The company traded as high as $6.59 and last traded at $6.55, 187,660 shares traded hands during trading. An increase of 19% from the average session volume of 157,955 shares. The stock had previously closed at $5.97.
Separately, ValuEngine raised shares of XCel Brands from a “sell” rating to a “hold” rating in a research report on Tuesday.
The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 2.90. The firm has a market capitalization of $119.04 million, a price-to-earnings ratio of -17.24 and a beta of 1.04. The business’s 50-day moving average price is $6.27.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Deutsche Bank AG increased its position in iCAD by 33.5% during the 4th quarter. Deutsche Bank AG now owns 35,923 shares of the technology company’s stock valued at $132,000 after purchasing an additional 9,023 shares during the period. IHT Wealth Management LLC purchased a new position in shares of iCAD in the 4th quarter worth approximately $48,000. Advisor Group Inc. grew its position in shares of iCAD by 96,087.0% in the 4th quarter. Advisor Group Inc. now owns 22,123 shares of the technology company’s stock worth $82,000 after buying an additional 22,100 shares during the last quarter. Spark Investment Management LLC purchased a new position in shares of iCAD in the 1st quarter worth approximately $185,000. Finally, Columbia Pacific Advisors LLC grew its position in shares of iCAD by 218.0% in the 1st quarter. Columbia Pacific Advisors LLC now owns 63,600 shares of the technology company’s stock worth $329,000 after buying an additional 43,600 shares during the last quarter. 18.98% of the stock is currently owned by institutional investors and hedge funds.
About iCAD (NASDAQ:ICAD)
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Further Reading: Golden Cross
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.